StockNow
CalendarLog in
Other

Novartis (NOVOB DC) discontinued development of vhb937 in amyotrophic lateral sclerosis (ALS) following results from the phase 2 Astrals study; vhb937 did not meet its primary or secondary endpoints

StockNow breaking-news AI analysis

Novartis discontinued development of vhb937 for amyotrophic lateral sclerosis after it failed to meet primary or secondary endpoints in the phase 2 Astrals study.

1 stocks
NVSNovartis AG$139.27Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

US officials reportedly met with Yemeni Houthis in Oman over the weekend, according to sources

U.S. Economy

US Export Prices MoM (Aug)(MM): 0.6% (exp. 0.5%, prev.-1.4%, rev. from -1.3%)

U.S. Markets

Apple (AAPL) reportedly considers return to server market, has spoke with Nvidia (NVDA) to use network tech, reports The Information

AAPLNVDA